Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled “Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach”|SUBJECT: Press Release
Source link
Revolutionary taking place